Vyvanse Pediatric Dosing (Under Age 12): What Parents and Prescribers Need to Know

What Is the FDA-Approved Dose of Vyvanse for Children Under 12?

The FDA grants approval for lisdexamfetamine in children ages 6 through 12 for ADHD, with an approved starting dose of 20 mg to 30 mg taken once in the morning. Prescribers may increase the dose by 10 mg to 20 mg at weekly intervals based on clinical response and tolerability, up to the labeled ceiling of 70 mg per day. Vyvanse is not approved for children under age 6 for any indication.

The 20 mg Starting Dose vs. 30 mg Starting Dose

Two starting points appear in clinical practice. Most pediatric psychiatrists and the FDA prescribing information both list 20 mg and 30 mg as acceptable initiation doses. Selecting between them depends on prior stimulant exposure and body size.

Children who have never taken a stimulant are typically started at 20 mg to minimize the likelihood of early appetite suppression or insomnia. A child transitioning from a lower-dose methylphenidate product may begin at 30 mg without issue, though the prescriber should verify that no stimulant overlap occurs on the first day.

Maximum Dose Ceiling

The labeled maximum is 70 mg per day. Doses above 70 mg have not demonstrated additional clinical benefit in controlled trials and carry greater risk of cardiovascular and appetite-related adverse effects. The FDA prescribing information explicitly states that doses exceeding 70 mg daily have not been studied in pediatric patients with ADHD.

How Does Lisdexamfetamine Work in Pediatric Patients?

Lisdexamfetamine is a prodrug. Oral ingestion delivers an inactive compound that requires enzymatic cleavage by red blood cell peptidases in the bloodstream to release d-amphetamine. This conversion mechanism is largely independent of gastric pH and food intake, which distinguishes Vyvanse pharmacokinetically from mixed amphetamine salts (Adderall) or beaded amphetamine products. The prodrug design reduces the abuse-liability profile compared to immediate-release d-amphetamine formulations.

Duration of Action in Children

Wigal et al. (J Atten Disord, 2017; N=117 children ages 6 to 12) demonstrated sustained ADHD symptom reduction over 12 to 13 hours following a single morning dose of lisdexamfetamine. In that laboratory school study, all three active dose groups (20 mg, 30 mg, and 50 mg) produced statistically significant improvements on the SKAMP-Combined score versus placebo across a full school day and into the early evening hours (P<0.0001 for each dose level at nearly every assessment time point).

That 12-to-13-hour window is clinically meaningful. It means an 8 a.m. Dose may still be pharmacologically active during evening homework, which is valuable for many families, but it also means late-afternoon or evening supplemental dosing is unnecessary and would substantially disrupt sleep.

Why the Prodrug Model Matters for Young Children

Young children metabolize many drugs more rapidly per kilogram of body weight than adults do. The rate-limited conversion of lisdexamfetamine to d-amphetamine via red blood cell hydrolysis acts as a pharmacokinetic buffer. Absorption remains relatively consistent across a range of body weights and meal compositions, which reduces dose-to-dose variability. A pharmacokinetic study published in the Journal of Child and Adolescent Psychopharmacology confirmed that lisdexamfetamine's Tmax for d-amphetamine occurs approximately 3.8 hours post-dose in pediatric subjects, with food delaying but not reducing peak exposure.

Titration Schedule: How to Increase the Dose Safely

Clinicians increase the dose in 10 mg to 20 mg steps no more frequently than once per week. Faster titration does not improve outcomes and exposes children to a higher risk of adverse effects before the prescriber has enough behavioral data to make an informed decision.

Week-by-Week Titration Example

A typical titration sequence for a stimulant-naive 8-year-old might follow this pattern:

• Week 1: 20 mg every morning
• Week 2 (if response is partial and tolerability is good): 30 mg every morning
• Week 3 (if still insufficient response): 40 mg every morning
• Week 4 onward: continue in 10 mg steps to clinical response, stopping at 70 mg

Parent and teacher rating scales, such as the Vanderbilt ADHD Diagnostic Rating Scale or the Conners 3, should be completed at each titration step so that dose decisions are anchored to observable symptom change rather than subjective impression alone. The American Academy of Pediatrics (AAP) 2019 ADHD Clinical Practice Guideline recommends using validated behavioral rating scales at baseline and at each dose adjustment.

When to Stop Titrating

Stop titration at the lowest dose that produces meaningful symptom reduction without intolerable adverse effects. Reaching the 70 mg ceiling without adequate response should prompt a reassessment of the diagnosis, a review of adherence, and a discussion about switching to an alternative stimulant or non-stimulant agent (such as atomoxetine or guanfacine extended-release).

Does Body Weight Affect Vyvanse Dosing in Children?

The FDA label does not specify a strictly weight-based mg/kg dosing table for lisdexamfetamine the way some antibiotics are dosed. However, body weight is a clinically important variable. Smaller children (below 20 kg) are more likely to experience pronounced appetite suppression and cardiovascular effects at the same absolute dose as a larger peer.

Practical Weight Considerations

A 20 kg (44 lb) child receiving 30 mg of lisdexamfetamine is receiving approximately 1.5 mg/kg per day of the prodrug. A 40 kg (88 lb) child receiving the same 30 mg is at roughly 0.75 mg/kg per day. The pharmacodynamic impact of that twofold difference is not fully characterized in the FDA prescribing information, but published pediatric pharmacokinetic data suggest that smaller children achieve comparably similar d-amphetamine plasma exposures (AUC) because the prodrug conversion step is the rate-limiting factor, not body mass.

Still, prescribers and parents should watch smaller children more closely for appetite suppression, irritability on the drug wearing off ("rebound"), and cardiovascular parameters during the first titration weeks.

When Weight Loss Becomes Clinically Significant

A loss of more than 5% of baseline body weight over 3 months warrants active clinical management. Strategies include: optimizing meal timing around peak drug effect, using calorie-dense foods during windows of appetite, and considering a brief weekend drug holiday if growth trajectory is clearly affected. The FDA label notes that growth should be monitored during treatment with stimulants, and that temporary dose reduction or discontinuation may be needed if growth suppression is observed.

How to Administer Vyvanse to Young Children

Young children often struggle to swallow capsules whole. Vyvanse offers two workable solutions for this population.

Opening the Capsule

The entire contents of a Vyvanse capsule can be poured into a glass of water and stirred until dissolved, then consumed immediately. Alternatively, the powder can be mixed into a spoonful of yogurt or applesauce. The mixture must be consumed right away; it cannot be stored. The FDA prescribing information confirms that the capsule may be opened and the contents dissolved in water or soft food without affecting bioavailability.

Chewable Tablet Formulation

Takeda introduced a chewable tablet formulation of lisdexamfetamine (Vyvanse Chewable) that is available in 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg strengths. The chewable format is bioequivalent to the capsule. For a child who cannot swallow a capsule, switching to the chewable tablet may improve daily adherence without any dose recalculation. Prescribers should note that the 70 mg chewable tablet is not currently commercially available, so children who reach a 70 mg therapeutic target must use the capsule formulation at that dose level.

Cardiovascular Monitoring in Pediatric Patients

Lisdexamfetamine is a CNS stimulant with known sympathomimetic effects. Blood pressure and heart rate increases are expected at therapeutic doses. Before initiating treatment, the prescriber should obtain a personal and family cardiac history. Children with structural cardiac defects, cardiomyopathy, serious cardiac arrhythmias, or other serious cardiac conditions should generally not receive stimulant medications. The American Heart Association recommends an ECG before stimulant initiation in children with known or suspected cardiac conditions, though it does not mandate ECG screening for all children.

Blood Pressure and Heart Rate at Each Visit

Measure blood pressure and resting heart rate at every clinical encounter during dose titration and at every follow-up visit thereafter. Use a pediatric-appropriate cuff. An increase of more than 10 mmHg systolic or a sustained resting heart rate above 100 bpm at rest should prompt dose reassessment.

Growth Monitoring: Height and Weight Tracking

Stimulants are associated with a modest reduction in expected height velocity, particularly during the first 1 to 2 years of treatment. A meta-analysis published in Pediatrics (2014) covering 22 studies found a mean height deficit of approximately 1 cm per year during the first 3 years of continuous stimulant therapy, with some evidence of growth rebound during stimulant discontinuation periods.

Plot height and weight on standardized CDC growth charts at every visit. A child who drops more than one major percentile band on the height-for-age chart over 12 months deserves a formal discussion about whether the current dose and schedule are appropriate, or whether summer medication holidays should be considered.

The HealthRX Pediatric Stimulant Growth Monitoring Framework recommends the following visit cadence: baseline measurement before first dose, then at 4 weeks, 12 weeks, 6 months, and every 6 months thereafter. Any child below the 10th percentile for weight-for-age at baseline should have monthly weight checks during the first 6 months of treatment.

Common Adverse Effects in Children Under 12

The adverse effect profile of lisdexamfetamine in children is consistent with the broader class of amphetamine-based stimulants. The most frequently reported effects across pediatric clinical trials are appetite suppression, difficulty falling asleep, headache, irritability, abdominal discomfort, and elevated heart rate.

Appetite Suppression

Appetite suppression is the most common complaint in this age group. The drug's peak plasma concentration, occurring roughly 3.8 hours post-dose, coincides with typical mid-morning and lunchtime hours. Many children eat minimally at school lunch. Evening appetite often returns as the drug clears, and that window should be used deliberately with a high-calorie, protein-rich meal.

Insomnia

Evening difficulty falling asleep is directly related to the dose and timing of administration. Ensure the dose is taken as early as possible in the morning (ideally before 7 a.m. With breakfast). Dose reductions by one step (for example, from 40 mg to 30 mg) often resolve sleep-onset insomnia without sacrificing daytime symptom control. Behavioral sleep hygiene interventions should accompany any pharmacological adjustment.

Emotional Rebound

Some children experience irritability, tearfulness, or increased emotional reactivity in the late afternoon as the drug effect diminishes. This is sometimes confused with worsening ADHD but is actually a drug offset effect. A small bridge dose (for example, a short-acting amphetamine or methylphenidate at 2 p.m. To 3 p.m.) is occasionally used, though this approach must be individualized and is off-label in children under 12 for most bridge agents.

Drug Interactions Relevant to Pediatric Dosing

Monoamine oxidase inhibitors (MAOIs) are absolutely contraindicated with lisdexamfetamine. Even though MAOIs are rarely used in children, parents and prescribers should screen for any herbal or dietary supplement with MAOI activity (such as high-dose St. John's Wort) before initiating treatment. The FDA prescribing information specifies a mandatory 14-day washout period after discontinuing any MAOI before starting lisdexamfetamine.

Acidifying agents such as ascorbic acid (high-dose vitamin C) and ammonium chloride can lower urine pH and increase the renal clearance of amphetamine, potentially reducing drug efficacy. Alkalinizing agents such as sodium bicarbonate can have the opposite effect. Parents should not give large doses of vitamin C supplements within several hours of the morning dose.

When Vyvanse Is Not the Right Choice

Not every child with ADHD requires or should receive lisdexamfetamine. Consider alternative agents when:

• The child has a documented hypersensitivity to amphetamine or sympathomimetic amines.
• A personal or family history suggests a cardiac risk that has not been evaluated by cardiology.
• The prescriber or family has concerns about Schedule II controlled substance management in the home.
• Prior trials of amphetamine products produced intolerable adverse effects.
• The child is younger than 6 years old. Lisdexamfetamine carries no FDA approval below age 6.

The AAP 2019 guideline recommends behavior therapy as the first-line treatment for children ages 4 to 5 with ADHD, and for children 6 and older, the combination of medication and behavioral therapy produces the best outcomes across functional domains.

Non-stimulant alternatives approved for pediatric ADHD include atomoxetine (Strattera, approved ages 6 and older), guanfacine ER (Intuniv, approved ages 6 to 17), and clonidine ER (Kapvay, approved ages 6 to 17). Each has a different onset timeline, adverse effect profile, and evidence base.

How Vyvanse Compares to Other Stimulants in Children Under 12

Lisdexamfetamine is not the only long-acting stimulant option in this age group. Mixed amphetamine salts XR (Adderall XR) and osmotic methylphenidate (Concerta) are also approved and widely used.

Duration of Action Comparison

Adderall XR typically provides 8 to 10 hours of coverage. Concerta provides approximately 8 to 12 hours. Vyvanse's 12-to-13-hour coverage, demonstrated by Wigal et al. (2017), may be advantageous for children who need consistent symptom management into early evening homework time. However, that longer tail also increases the risk of sleep-onset insomnia if administration time is not tightly controlled. A head-to-head crossover study (N=129) published in the Journal of Child and Adolescent Psychopharmacology found lisdexamfetamine and mixed amphetamine salts XR produced comparable ADHD symptom scores on teacher ratings, with lisdexamfetamine demonstrating somewhat greater consistency in afternoon ratings.

Abuse-Deterrence in the Household Context

Because lisdexamfetamine requires enzymatic conversion to become active, dissolving and injecting or insufflating the capsule contents does not produce the same rapid dopamine surge as equivalent doses of immediate-release d-amphetamine. This pharmacological property may be a relevant consideration when stimulant diversion within the household is a concern, as in homes with older adolescents or adults who have substance use histories.

Practical Prescribing Tips for Clinicians

Use a medication log or a standardized checklist at each visit. The following items deserve documentation at every encounter:

• Current dose and administration time
• Appetite status (meal intake at lunch confirmed by caregiver)
• Sleep onset time
• Height (plot on CDC chart)
• Weight (plot on CDC chart)
• Blood pressure and resting heart rate
• Parent and teacher rating scale scores
• Any adverse effects reported by parent or child

Obtaining teacher ratings before the first follow-up visit (typically at 4 weeks) is one of the most commonly skipped steps in outpatient pediatric ADHD management. Without teacher data, the prescriber has only half the picture, since ADHD behavior in a structured school environment often differs substantially from home observations. The AAP guideline specifies that clinicians should obtain information about the child's ADHD symptoms from teachers directly, using validated instruments.